Share Source: AP Photo/Evan Vucci We'll get to Biden in a moment, but first some thoughts on policy and messaging. US administration of Johnson & Johnson's safe, effective, one-dose vaccine was paused for more than a week by regulators, based on concerns about exceptionally rare potential blood clotting side effects. After a review, which found just 15 such cases out of the eight million Americans who'd received the J&J shot, the pause was lifted late last week, with a warning. Was this "abundance of caution"-inspired policy the right move, or a mistake? We've argued that it was the wrong...